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Executive Summary 
The prevention of disease through immunization is one of the most successful and cost-effective public 
health interventions in history. However, despite significant progress made over the last decade, global 
immunization rates remain low in many parts of the world. Almost one-quarter of children worldwide lack 
access to life-saving vaccines, and every year 2.4 million children die from vaccine-preventable diseases 
(VPDs).1 The problem is particularly severe in sub-Saharan Africa, where each year 8.3 million children 
do not receive the most basic vaccines.2 This region suffers one of the highest per capita burdens of 
VPDs in the world, with only 70 percent of children under age one receiving the diphtheria-tetanus-
pertussis (DTP3) vaccine, the global standard used to measure immunization coverage.3 
Critical deficiencies in the health workforce in many African countries underpin and exacerbate the 
challenges to vaccine delivery.4 In particular, limited immunization management capacity presents an 
acute barrier to expanding vaccine coverage.5 In many African countries, formal training for immunization 
managers is low quality, sporadic, or non-existent.6 Tackling issues of health worker capacity and 
improving access to vaccination are critical if global efforts to achieve the United Nations (UN) Millennium 
Development Goal 4—a two-thirds reduction of mortality in children under five—are to be successful.  
In response to chronic under-capacity in the immunization workforce in Africa, Merck launched the Merck 
Vaccine Network-Africa (MVN-A).7 Funded by The Merck Company Foundation and endorsed by the 
GAVI Alliance (GAVI), MVN-A was a ten-year, $4.8 million philanthropic initiative that provided 
customized, hands-on training to immunization managers in Kenya, Mali, Uganda, and Zambia. With the 
aim of enabling capacity building and two-way learning, each MVN-A program was managed and 
administered by two primary institutions, one in the African country and one in the United States or 
Europe. In turn, these institutions developed broader collaborative partnerships with other national 
stakeholders including ministries of health and education, non-governmental organizations (NGOs), 
medical and nursing schools, and multilateral organizations such as the World Health Organization 
(WHO) and the United Nations Children’s Fund (UNICEF). Employing a train-the-trainer approach, the 
program focused on improving the knowledge, skills, and confidence of immunization managers, who in 
turn provided training and support to more junior health workers.  
                                                       
1 “Vaccine-Preventable Diseases Overview,” Bill & Melinda Gates Foundation, 
http://www.gatesfoundation.org/vaccines/pages/overview.aspx. 
2 IFPMA, “Merck Vaccine Network - Africa (MVN-A),” http://partnerships.ifpma.org/partnership/merck-vaccine-network-africa-
mvn-a. 
3 UNICEF and WHO, “Immunization Summary: A statistical reference containing data through 2009,” (2011). 
4 Bernhard Liese and Gilles Dussault, “The State of the Health Workforce in Sub-Saharan Africa: Evidence of Crisis and 
Analysis of Contributing Factors,” in Africa Region Human Development Working Paper Series, ed. The World Bank Africa 
Region (2004). 
5 UNICEF et al., “Mid-Level Management Training in Immunization in the African Region 2000-2004: Summative Evaluation,” 
(2005). 
6 Ibid. 
7 Merck is known as MSD outside of the United States and Canada. 
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Between 2003 and 2012, MVN-A facilitators trained more than 1,600 vaccine delivery workers, including 
close to 150 trainer-of-trainers, nearly 1,000 immunization managers, and over 400 additional health 
workers. Studies of pre- and post-training test scores indicate that all four national programs were 
successful in improving the knowledge and skills of trainees. Furthermore, overall immunization coverage 
improved in areas where the MVN-A trainings were conducted. While more difficult to quantify, evidence 
also exists that the program improved health worker morale, a particularly valuable outcome in resource-
constrained health systems suffering from low motivation and high turnover. 
 
 
As the MVN-A program comes to an end, Merck’s experience designing and supporting the initiative can 
offer valuable lessons for other actors in the immunization and broader global health fields who are 
engaged in or planning similar work. Specifically, we identify seven forward-looking lessons that can 
increase the effectiveness and sustainability of programs to build the capacity of the vaccine workforce in 
developing countries: 
1. Conduct a rigorous needs assessment to anchor efforts in local needs and priorities; 
2. Perform ongoing monitoring and evaluation (M&E) to enable programs to adapt, improve, and 
generate evidence of impact to attract new partners and funding; 
3. Create a sustainability plan at the outset to ensure that program impact is maintained beyond 
the conclusion of initial funding; 
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4. Embed programs into local health systems to ensure that investments leverage existing 
infrastructure, relationships, and resources, and that impact can be sustained beyond the life of the 
program; 
5. Employ locally-adapted curricula and appropriate teaching techniques to maximize transfer 
and retention of relevant knowledge; 
6. Incorporate supportive supervision into programs to ensure that transferred knowledge is 
maintained and acted upon; 
7. Facilitate and support regular convening and communication, enabling continuous learning for 
improvement. 
In addition to describing the approach taken by MVN-A and the results achieved in the four focus 
countries, this paper provides additional detail on each lesson, supported by case studies from the MVN-
A experience.  
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Introduction 
In 2003, Merck launched the Merck Vaccine Network – Africa (MVN-A), a multi-year, multi-country 
initiative designed to contribute to improving the immunization workforce in four African countries: Kenya, 
Mali, Uganda, and Zambia. The MVN-A program complements a number of other significant investments 
by The Merck Company Foundation to improve access to health in Africa and around the world, including:  
• The Merck Mectizan Donation Program: Merck has committed to provide medicine for the treatment 
of onchocerciasis (or river blindness) to all who need it, for as long as needed. Established in 1987, this 
is the longest-running, disease-specific drug donation program and public/private partnership of its 
kind. 
• The African Comprehensive HIV/AIDS Partnership (ACHAP): Since 2000, ACHAP has supported 
Botswana’s national HIV/AIDS strategy to prevent new HIV infections and reduce morbidity and 
mortality associated with the disease.  
• The BroadReach Institute for Training and Education (BRITE): Merck is supporting implementation 
and management of BRITE’s Management and Leadership Academy (MLA) program in Zambia, which 
teaches critical management and leadership skills for health care professionals in order to strengthen 
the capacity of local health systems.  
• The Earth Institute's Millennium Villages Community Health Worker Training Program: Merck 
provides support for this program, strengthening community health services for more than 400,000 
people in 10 African countries. 
The MVN-A program received $4.8 million in philanthropic support from Merck over a 10-year period from 
2003 to 2012.8 This decade of experience provides useful insights for other organizations that are 
planning or implementing similar programs elsewhere.  
The objective of this paper is to document the impact and share the lessons learned from MVN-A with the 
broader global health field. In addition to describing the approach taken by MVN-A and the results 
achieved in the focus countries, we identify seven key lessons for designing and implementing 
immunization workforce strengthening programs. Each of these lessons is grounded in Merck’s 
experience with MVN-A, drawing from both its successes and its challenges. Together, these lessons 
offer a blueprint for increasing the effectiveness and sustainability of similar initiatives to build the capacity 
of the health workforce in developing countries. 
The report draws on data and insights gathered from interviews with nearly 40 program leaders and 
stakeholders from across the four focus countries in Africa, the U.S., and the EU. These individuals 
include program directors, training officers, trainees, ministry of health (MOH) officials, multilateral 
partners, and members of the core Merck team who were involved in the design and administration of the 
                                                       
8 MVN-A was a philanthropic effort supported by The Merck Company Foundation; Merck generated no commercial benefit 
from the program. 
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program. In addition, we synthesized data from more than 50 documents provided by in-country program 
leadership, including grant applications, unpublished grantee progress reports and final evaluations, and 
published journal articles.  
As Merck sunsets its decade-long investment in MVN-A, The Merck Company Foundation commissioned 
this paper in order to identify, document, and share the results of the MVN-A program and relevant 
lessons for the field.  
The Vaccine Workforce Challenge 
Vaccination Is a Highly (Cost-) Effective Public Health Intervention 
The prevention of disease through immunization is one of the most successful public health interventions 
in history, saving three million lives annually—second in its reach only to the provision of clean drinking 
water.9 Margaret Chan, Director General of WHO, describes vaccines as “one of the greatest success 
stories in global public health.”10 Increases in immunization coverage can extend life expectancy, 
decrease health care costs, and increase productivity for both vaccinated individuals and whole 
communities.11 Immunization also is one of the most cost-effective health interventions available today; 
every dollar spent on vaccines results in up to thirty dollars saved on later treatment.12 New vaccines—
including for rotavirus diarrhea, human papillomavirus, and pneumococcal disease—promise to extend 
this powerful effect to other disease burdens. 
Sub-Saharan Africa Bears a Disproportionate Burden of Vaccine-Preventable Disease  
Despite ample evidence of the efficacy of vaccines, global immunization rates remain low. Almost one-
quarter of children worldwide lack access to life-saving vaccines; as a result, every year, 2.4 million 
children die from vaccine-preventable diseases.13 Sub-Saharan Africa has one of the highest per capita 
burdens of VPDs in the world, with only 70 percent of children under age one receiving the DTP3 vaccine, 
the global standard for immunization coverage.14 Further improving access to immunization is critical if 
global efforts to achieve a two-thirds reduction of mortality in children under five by 2015 (Millennium 
Development Goal 4) are to be successful.15 
 
                                                       
9 “Q-Series: Global Pharmaceuticals,” in UBS Investment Research (UBS, 2012). 
10 Margaret Chan, “Saving Lives with Immunization,” (Bill & Melinda Gates Foundation, 2011). 
11 UNICEF, WHO, and World Bank, “State of the world's vaccines and immunization,” (Geneva: The World Bank, 2009). 
12 “Q-Series: Global Pharmaceuticals.” 
13 “Vaccine-Preventable Diseases Overview.” 
14 UNICEF and WHO, “Immunization Summary: A statistical reference containing data through 2009.” 
15 WHO, “Immunization, Vaccines and Biologicals: Millennium Development Goals,” 
http://www.who.int/immunization/newsroom/mdg/en/index.html. 
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In the last decade, the world has made substantial progress in tackling low immunization coverage rates. 
Thanks to large, sustained investment by agencies and partnerships such as the GAVI Alliance, coverage 
of DTP3 in low-income countries rose from 66 percent in 2000 to an all-time high of 79 percent in 2010.16 
Nevertheless, a significant coverage gap remains in sub-Saharan Africa and the challenges to progress 
are numerous. Poor distribution and delivery structures, including disruptions to the cold chain that is 
essential to transporting vaccines in a temperature controlled environment, have contributed to reduced 
vaccine potency and access. Poor surveillance and monitoring also have made it difficult to forecast 
demand, set priorities, and identify disease outbreaks.17  
Limited Workforce and Management Capacity in Many African Countries Hinders 
Progress 
Critical deficiencies in the health workforce in many African countries underpin and exacerbate these 
challenges.18 Africa has only 3 percent of the world’s health workers to address 24 percent of the global 
disease burden; this disparity is troubling as evidence exists that the number and quality of health care 
workers is positively associated with vaccine coverage.19,20 Too often, training for under-resourced and 
over-stretched health workers is low quality, sporadic, or non-existent.21,22 Furthermore, health systems 
often suffer from high staff turnover, urban-rural imbalances, and demotivating working conditions.23 
Limited immunization management capacity within health systems presents a particularly acute barrier to 
expanding vaccine coverage.24 Moreover, efforts to address this need through training are hampered by 
inadequate and inconsistent financing.25 In many African countries, formal training for immunization 
managers has not been conducted since the mid-1990s.26 In 2004, WHO identified capacity building to 
improve managers’ planning, management, monitoring, and evaluation skills as a critical strategy for 
improving immunization services, particularly in decentralized systems where resource allocation 
decisions are made at a local level.27 
                                                       
16 GAVI Alliance, “GAVI Helps DTP3 Coverage Rise After Stagnation,” 
http://www.gavialliance.org/library/news/roi/2010/gavi-helps-dtp3-coverage-rise-after-stagnation/. 
17 UNICEF, WHO, and World Bank, "State of the world's vaccines and immunization." 
18 Liese and Dussault, “The State of the Health Workforce in Sub-Saharan Africa: Evidence of Crisis and Analysis of 
Contributing Factors.” 
19 GAVI Alliance, “Health System Strengthening Support,” http://www.gavialliance.org/support/hss/. 
20 WHO, “The World Health Report 2006: Working Together for Health,” (Geneva, 2006). 
21 UNICEF, “Mid-Level Management Training in Immunization in the African Region 2000-2004: Summative Evaluation.”  
22 Norad and GAVI, “Alleviating System Wide Barriers to Immunization: Issues and Conclusions from the Second GAVI 
Consultation with Country Representatives and Global Partners,” (Oslo, Norway, 2004). 
23 Liese and Dussault, “The State of the Health Workforce in Sub-Saharan Africa: Evidence of Crisis and Analysis of 
Contributing Factors.” 
24 UNICEF, “Mid-Level Management Training in Immunization in the African Region 2000-2004: Summative Evaluation.” 
25 Ibid. 
26 Ibid. 
27 Ibid. 
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The Merck Vaccine Network – Africa Was Developed to Address the Workforce 
Challenge 
In response to chronic under-capacity in the immunization workforce in Africa, Merck launched the Merck 
Vaccine Network – Africa. Funded by The Merck Company Foundation and endorsed by GAVI Alliance, 
the program supported collaborative partnerships in the development and implementation of Expanded 
Program on Immunization (EPI) management training programs in Kenya, Mali, Uganda, and Zambia.  
This philanthropic commitment reflects Merck’s dedication to improving access to medicines, vaccines, 
and health care in the developing world. It built on the company’s longstanding dedication to reducing the 
morbidity and mortality of children in low-income countries, and was specifically designed to help achieve 
the UN Millennium Development Goals, including reducing by two-thirds the mortality rate among children 
under five by 2015. 
MVN-A Program Design and Implementation 
MVN-A Sought to Build Management Capacity in Four African Immunization Programs 
The approach of the MVN-A program 
was to provide customized training for 
mid- to high-level immunization 
managers working in sub-Saharan 
Africa in order to increase health 
worker capacity and improve vaccine 
delivery. The program was designed 
to support and build capacity for EPI, 
a global effort initiated by WHO in 
1974 with the aim of ensuring that all 
children in all countries benefit from 
life-saving vaccines. 
Merck initiated a competitive grant 
application process, which 
emphasized strength of partnerships, 
to select countries for program 
implementation. In 2003, Merck 
established MVN-A training programs in Kenya and Mali. Following a second competitive grant 
application process in 2007, two additional programs were established in Uganda and Zambia. The Merck 
Company Foundation provided funding of $200,000 annually to each program, for a total of $4.8 million 
over ten years.  
 
A 2009 Merck Vaccine Network-Zambia training session 
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Each MVN-A program adapted the existing mid-level manager EPI training modules published by the 
WHO Regional Office for Africa. The training courses covered a wide range of topics, including storing 
and handling vaccines safely, forecasting community needs to ensure an adequate vaccine supply, 
planning and conducting disease surveillance activities, and providing on-site supportive supervision to 
health workers. Some programs also created new modules based on feedback gathered during a local 
needs assessment, which each program completed.  
After conducting a series of customized training of trainers sessions, each program identified a pool of 
highly effective facilitators to administer training at the national, provincial, and district levels across each 
focus country. MVN-A training facilitators included senior Ministry of Health EPI program administrators, 
medical and nursing school professors, medical training college instructors, WHO EPI personnel, cold 
chain equipment technicians, and former MVN-A graduates with experience training health workers at the 
operational level. 
Each MVN-A program was managed and administered by two primary institutions, one in the African 
country and one in the United States or Europe. The primary partnerships were as follows: 
• Kenya, a collaboration between Indiana University School of Medicine (Indianapolis, Indiana, U.S.) and 
Moi University School of Medicine (Eldoret, Kenya); 
• Mali, a collaboration between the University of Maryland School of Medicine Center for Vaccine 
Development (Baltimore, Maryland, U.S.) and Centre pour le Développement des Vaccins-Mali 
(Bamako, Mali); 
• Uganda, a collaboration between The Task Force for Child Survival and Development, Emory 
University (Decatur, Georgia, U.S.) and Makerere University School of Public Health (Kampala, 
Uganda); and 
• Zambia, a collaboration between Brighton and Sussex University Hospitals NHS Trust (Brighton, U.K.) 
and the University of Zambia School of Medicine (Lusaka, Zambia). 
The Partnership Structure Was Integral to the Program’s Design 
The four MVN-A programs were designed as partnerships between local African institutions and centers 
of expertise in the United States and Europe. This unique structure leveraged the strengths of each 
partner. Anchoring efforts in local institutions enabled the programs to benefit from deep in-country 
knowledge and existing networks. Involving global centers of excellence provided technical assistance 
and expertise from leading academics, building the capacity of African organizations. 
The two-way learning that this model enabled was hailed by many stakeholders as a valuable aspect of 
the program. Professor Samba O. Sow, Program Principal Investigator for the Mali program (MVN-Mali) 
credits his U.S. collaborators with “strengthening our program administration, helping us write grants, and 
advising us on our finance and accounting systems.” Meanwhile, U.S.-based colleagues cite the 
knowledge and experience of their African counterparts as vital to building local relationships, informing 
needs assessment, and setting program priorities. Dr. Fred Wabwire-Mangen, Co-Director of the Uganda 
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program—known as the Uganda Immunization Training Program, or UITP in-country—reflected, “The 
partnership was a central piece of the program. The quality of collaboration was excellent.” 
The Primary Partnerships Were Supplemented by Robust Networks of In-Country 
Partners 
The primary partners in each MVN-A program established a broad network of local stakeholders, 
including ministries of health and education, NGOs, medical and nursing schools, and multilateral 
organizations such as WHO and UNICEF. These important connections helped the programs establish 
credibility, leverage local knowledge, and ensure alignment with existing priorities for immunization 
delivery. 
Each MVN-A program formed a Technical Advisory Group (TAG), bringing together key stakeholders to 
inform program strategy, provide guidance on curriculum content, and identify promising trainers and 
trainees. The TAG for the Zambia program (MVN-Z), for instance, included representatives from the 
Ministry of Health, WHO, UNICEF, The United States Agency for International Development (USAID), 
local nursing schools, local NGOs, and leading pediatricians. Professor Mary Shilalukey Ngoma, Co-
Director for MVN-Z, describes the essential functions filled by the TAG: 
It played an invaluable role in guiding the program – both in determining our overall 
strategy, and with the day-to-day work. We met at the beginning of each year and at 
regular intervals throughout, planned together and received input on what issues and 
activities were critical, what could wait, and what was not relevant to Zambia's EPI 
program. 
Trainings were regularly attended or co-taught by local representatives from WHO and EPI, providing an 
important stamp of credibility for the program, and helping to elevate the issue of childhood immunization 
within the local public health agenda. 
A Train-the-Trainer Model Was Employed to Leverage Limited Resources 
The MVN-A program implemented a train-the-trainer approach, focused on improving the knowledge, 
skills, and confidence of immunization managers, who in turn provided training and support for more 
junior health workers. The primary partner institutions in each country, informed by additional local 
stakeholders, identified a cadre of facilitators to deliver national-, provincial-, and district-level training to 
managers nationwide.  
Dr. Fred Wabwire-Mangen, Co-Director of the Uganda program, cites the benefits of this approach: 
Training of trainers was highly effective because it allowed us to implement cascade 
training throughout all levels of the health care system. At the national level, we worked 
with WHO to create a small team that facilitated the training of our larger national team of 
trainers. This team, in turn, trained managers throughout the country. Those district 
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managers then returned to their districts and trained the workers below them, both 
formally and in a hands-on fashion. In this way, we generated a spill-over effect. 
Given finite funding, this cascade approach to training allowed the program to maximize the number of 
health workers reached through this investment, and allowed the facilitators to provide much-needed 
ongoing training in response to high turnover in the field.  
Results and Impact 
At MVN-A’s Launch, National Immunization Programs Suffered from Major 
Deficiencies 
At the outset of the MVN-A program, the need for comprehensive immunization delivery training in sub-
Saharan Africa was substantial. Studies showed that past EPI training activities were infrequent, under-
funded, and provided only on an ad-hoc basis, using curricula and reference materials that were 
incomplete or outdated.28 For example, in Kenya, there had been no comprehensive training for 
immunization managers in over 15 years.29 Given high turnover rates in the sector, most current health 
workers had never received immunization training at all. Partly as a result of this dearth of training, 
vaccination rates remained low and quality of immunization delivery was poor. 
Professor Samba O. Sow of MVN-Mali describes the situation in that country before the training: 
When MVN-A began, the vaccine coverage level in some of the places we worked was 
below 50 percent. Half of the kids who did not receive full coverage had never had a 
single immunization. That is a disaster. Routine EPI was supposed to have been running 
in Mali since 1986, but in 2003, even in Bamako, we found babies that had never been 
vaccinated. We also found health workers leaving vaccines on their desk all day long 
when it was 110 degrees outside. Even though there are monitor strips on the vaccine 
that show if it has been compromised by exposure to inappropriate temperatures, health 
workers didn’t know how to read them. We would ask the EPI supervisors if they would 
give a baby that vaccine, and they would say, “Oh, yes, we would.”  
MVN-A Contributed to Significant Improvements in Quality and Reach of Vaccination 
Programs 
Although the use of different monitoring and evaluation approaches in each MVN-A focus country makes 
it impossible to draw direct comparisons across programs, there is evidence that MVN-A effectively 
                                                       
28 D. Nshimirimana et al., “EPI Training Needs Assessment in 12 African Countries (2002-2004),” Communicable Diseases 
Bulletin 3 (2005).  
29 S.O. Ayaya et al., “Training Needs for Mid-Level Managers and Immunisation Coverage in Western Kenya,” East African 
Medical Journal 84, no. 7 (July 2007). 
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increased the skills and knowledge of EPI workers and contributed to improved immunization rates in the 
geographies where it was implemented (see Figure 2). Over the course of the program, MVN-A 
facilitators trained more than 1,600 EPI workers, including over 150 trainer-of-trainers, over 1,000 
immunization managers, and over 200 additional health workers.  
All four national programs demonstrated success in improving the knowledge and skills of trainees. The 
Zambia program demonstrated statistically significant increases (P-value of less than .001) in pre- and 
post-training test scores in almost every area tested.30 The Kenya (MVN-K), Mali, and Uganda programs 
also reported substantial improvements in test scores, of between 5 and 15 percentage points, following 
training.31,32,33 These improvements were seen over a wide range of different subject modules, ranging 
from immunization safety to planning and budgeting. Moreover, the participants themselves saw the 
training as valuable and effective. For example, in Uganda, some 99 percent of program graduates 
indicated that they had a better understanding of how to deliver immunization services, while 96 percent 
felt better equipped to provide high-quality programs.34 
Although likely attributable to a number of factors, overall immunization coverage improved in areas 
where the MVN-A trainings were conducted. In Uganda and Kenya, national coverage improved by 7 and 
17 percentage points, respectively.35,36 Likewise, a study of a village in Mali where the program was 
implemented revealed a 13 percentage point increase in DTP3 and an 18 percentage point increase in 
measles vaccine coverage.37 In Zambia, among previously poor-performing districts (defined as having 
coverage of less than 60 percent), 83 percent improved coverage to above 70 percent, and an additional 
13 percent improved coverage to between 60 and 70 percent.38 Kenya and Mali also saw a reduction in 
the dropout rate from a regularly administered course of pentavalent-1 and measles vaccination; the 
dropout rate declined by 6 percentage points in Kenya and fell to 5 percent or less in all centers receiving 
supportive supervision in Mali.39,40  
Although more difficult to measure, there is also evidence that the MVN-A Program improved health 
worker morale, a particularly valuable outcome in resource-constrained health systems suffering from low 
motivation and high turnover. Dr. James Conway, Co-Director of MVN-K, explains: 
                                                       
30 G. Phiri et al., “Merck Vaccine Network Zambia 2011 Annual Progress Report,” Unpublished MVN-A Document (2012). 
31 The Uganda Immunization Training Program, “Uganda Immunization Training Program Annual Progress Report Year 4, 
November 2010-October 2011,” Unpublished MVN-A Document (2011).  
32 J.B. Milstien et al., “Strengthening Immunization in a West African Country: Mali,” Education for Health 20, no. 3 
(November 2007).  
33 MVN-K, “Merck Vaccine Network-Africa Additional Information,” Unpublished MVN-A Document (2007).  
34 Margaret Kemigisa, “The Uganda Immunization Training Program Final Evaluation Report,” Unpublished MVN-A 
Document (February 2012).  
35 Ibid. 
36 E.A. Liechty et al., “Final Report-Merck Vaccine Network-Africa: Kenya Collaboration,” Unpublished MVN-A Document 
(2012). 
37 Milstien, “Strengthening Immunization in a West African Country: Mali.” 
38 Merck Vaccine Network-Zambia, “Merck Vaccine Network Zambia: A Summary Report of Achievements (2007-2012),” 
Unpublished MVN-A Document (2012). 
39 MVN-K, “Merck Vaccine Network-Africa Additional Information.” 
40 Julie Milstien et al., “Supportive Supervision Activities in Mali Improve the Quality of Immunization Services,” Unpublished 
MVN-A Document (2011-2012). 
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It was difficult to quantify but there was clearly confidence and pride in being associated 
with the program. Trainees felt that they were part of something important. It was 
palpable to me how people participating in these training seemed to feel empowered and 
proud to be an immunization manager responsible for the health of people in Kenya. 
Lessons for Future Programs 
Seven Key Lessons for Improved Program Effectiveness and Sustainability 
Merck’s experience designing and supporting the MVN-A program offers valuable lessons for other actors 
in the immunization and broader global health fields who are engaged in or planning future, similar work. 
Specifically, we identify seven key lessons, which can help ensure that immunization delivery training 
programs are effective and that the impact achieved is sustainable: 
1. Conduct a rigorous needs assessment to anchor efforts in local needs and priorities; 
2. Plan for and perform ongoing monitoring and evaluation (M&E) to enable programs to adapt 
and improve, and generate evidence of impact to attract new partners and funding; 
3. Create a sustainability plan at the outset to ensure that program impact is maintained beyond 
the conclusion of initial funding; 
4. Embed programs into local health systems to ensure that investments leverage existing 
infrastructure, relationships, and resources, and that impact can be sustained beyond the life of the 
program; 
5. Employ locally-adapted curricula and appropriate teaching techniques to maximize transfer 
and retention of relevant knowledge; 
6. Incorporate supportive supervision into programs to ensure that transferred knowledge is 
maintained and acted upon; 
7. Facilitate and support regular convening and communication, enabling continuous learning for 
improvement. 
Below, we discuss each of these key lessons in greater depth and illustrate them with relevant examples 
from the MVN-A program.  
1. Conduct a Rigorous Needs Assessment 
A robust needs assessment, anchored in data and input from local stakeholders, is essential to ensure 
that program activities and resources are deployed wisely. The MVN-A programs in Kenya, Mali, Uganda, 
and Zambia all conducted needs assessments prior to program implementation to inform strategic foci by 
identifying the most pressing gaps in immunization training and coverage.  
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MVN-Z, for example, used the results of its needs assessment to prioritize districts for training. The 
program ranked each district in Zambia according to coverage trends over an eight-year period for four 
critical antigens: BCG, OPV3, DPT3, and measles (see Figure 3).49 MVN-Z then selected for training 
those districts with the lowest immunization coverage rates, with 36 of 72 districts ultimately included. The 
program also paired high-performing and low-performing districts for the purpose of peer learning, 
providing support for ongoing “supportive visits” between districts.  
 
 
The Kenya program conducted a needs assessment to identify the most critical gaps in immunization 
knowledge, then customized program curriculum based on the results. MVN-K surveyed 83 immunization 
managers about their perceptions of the strengths, weaknesses, and areas for improvement in the 
Kenya Expanded Programme on Immunization (KEPI). The respondents frequently cited knowledge of 
cold chain maintenance as a critical gap that needed to be addressed. Professor Edward A. Liechty, Co-
Director of MVN-K, explains: 
The needs assessment revealed very clear demand for better understanding of the cold 
chain system. When a refrigerator would break down, the immunization workers would 
                                                       
49 Needs assessment coverage survey included years 2000-2007. 
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have to ship it several hundred kilometers for repair, which would take weeks, only to find 
out the cause was something minor that they could have repaired themselves if they’d 
had the training. 
In response to the data gathered in the needs assessment, MVN-K developed a supplemental training 
module focused specifically on cold chain maintenance, a subject not covered in standard WHO training 
materials. The module also included hands-on training on simple refrigerator repairs, which was identified 
by managers as a significant need.50  
2. Plan for and Perform Ongoing Monitoring and Evaluation (M&E)  
In addition to conducting an initial needs assessment, planning for and implementing ongoing monitoring 
and evaluation is also critical to program success: by systematically tracking and reviewing progress, 
programs can adapt and improve in response to new insights, as well as demonstrate success and 
positively position the program for potential future funding. M&E contributed to the success of the MVN-A 
program in both ways.	  
For example, an interim impact assessment conducted by MVN-Mali identified key deficiencies in 
information transfer from the national and regional levels to the peripheral health workers who were 
responsible for the administration of most vaccines.51 This finding informed the program’s decision to 
employ additional training techniques to reinforce learnings and improve performance through guided 
observation and feedback (see section “Incorporate Supportive Supervision,” below, for additional detail).  
MVN-K provides an example of using M&E both to make real-time programmatic adjustments and to 
attract partners and funding. After each training session, the program directors and all trainers gathered 
to discuss what worked well, what did not, and ideas for improvement. The suggestions from these in-
depth conversations, along with feedback gathered via survey from all training participants, were 
immediately incorporated into future training sessions. As Dr. James Conway, Co-Director of MVN-K, 
explains, “We were constantly gathering and using data to tweak and improve the program.”  
Furthermore, MVN-K shared with key stakeholders evidence collected on the success of the program, 
including pre- and post-training survey data and annual reports. This evidence of success was critical to 
building relationships with a number of important organizations. Based on the strength of these 
relationships and the demonstrated impact of the program, three stakeholders—KEPI, WHO, and 
USAID—have committed to the continued funding and implementation of training sessions after the 
completion of the MVN-A program.  
A substantial weakness in MVN-A’s implementation of M&E, however, was the lack of consistent data 
gathering and reporting across the four countries. By design, Merck did not prescribe an evaluation 
methodology or standardized metrics, allowing each country program to assess impact as it saw fit. While 
this approach had the advantage of maximizing flexibility and allowing for customization to the local 
                                                       
50Ayaya, “Training Needs for Mid-Level Managers and Immunisation Coverage in Western Kenya.” 
51Milstien, “Strengthening Immunization in a West African Country: Mali.” 
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contexts, it also resulted in an inability to determine standard benchmarks for success or directly compare 
progress across countries.  
3. Create a Sustainability Plan at Program Outset 
As with any externally funded 
program, it is essential to develop a 
long-term plan for sustainability in 
order to ensure that progress and 
impact are maintained once initial 
funding has been concluded. As 
Merck’s decade-long commitment to 
MVN-A draws to an end, Dr. Adel A.F. 
Mahmoud, former President of Merck 
Vaccines, who was instrumental in the 
program’s design, reflects upon an 
important lesson learned: “If the path 
to sustainability isn’t clear, there is a 
risk that progress will backslide once 
initial funding concludes.” 
Without clear sustainability plans in 
place from the start, the four MVN-A 
country programs now face varying challenges in maintaining the impact achieved to-date. Given the high 
rate of turnover among health care workers in sub-Saharan Africa, training sessions must continue to be 
held regularly, which of course requires commitment of ongoing funding. The MVN-A program in Kenya 
has been most successful in obtaining additional resources, and continues to conduct training sessions 
after the conclusion of funding from The Merck Company Foundation, with trainees nominated and fully 
financially supported by the Ministry of Health Division of Immunization and Vaccines. Other country 
programs are in the process of securing additional funding to continue training efforts.  
From the outset, Merck intended to provide multi-year seed funding for MVN-A, launching and growing 
the program, demonstrating impact, and “priming the pump” for additional funders to support the initiative 
as it gained momentum and scale. As Brenda D. Colatrella, Executive Director of Merck’s Office of 
Corporate Responsibility, points out, however, “You can't just put off addressing sustainability. You have 
to define it early and take responsibility for it. You cannot expect the program to automatically continue if 
you haven’t planned appropriately for sustainability.” 
From the earliest stages of program design, it is essential to develop a sustainability plan that clearly 
articulates the transition of funding responsibility and serves as a road map for the cultivation of 
relationships with in-country and global stakeholders that may eventually take ownership for the 
program’s long-term success. The complementary implementation of other lessons provided in this paper 
 
A UITP-trained health worker immunizes a child 
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– including performing ongoing M&E (see above) and embedding programs into local health systems (see 
below) – also helps position programs to attract resources and achieve long-term sustainability.  
4. Embed Programs into Local Health Systems 
A common mistake made by many development initiatives is to establish independent programs rather 
than integrating new efforts into existing systems and processes. This approach poses two important 
risks that ultimately limit program effectiveness and sustainability. First, the approach fails to leverage the 
substantial accumulated knowledge and experience that resides in existing health systems. Second, it 
makes it difficult to maintain impact beyond the life of the initiative: parallel structures require ongoing 
funding which may not be available in resource-constrained environments, even in the presence of 
evidence of success. MVN-A took steps to avoid both of these risks. Dr. Conway explains: 
The biggest mistake that has been made in global health, and especially in vaccines, is 
thinking that outsiders have the answers. True integration with local partners is critical. In 
the case of MVN-A, these were true partnerships, not just a U.S. program going in to 
implement something.  
For instance, implementation of MVN-K was deeply integrated within the MOH and the existing KEPI 
program. By design, the program targeted the most critical three to five vaccine managers in each district, 
not only positioning them to train others and thus magnifying country-wide impact, but also ensuring buy-
in from key government representatives. KEPI officials not only attended and participated in every training 
session, but also identified promising trainees and flagged ongoing training needs. As further evidence of 
its commitment to the program, the MOH’s Division of Vaccines and Immunizations nominated and 
financially supported fully two-thirds of the most recent train-the-trainers during Merck’s sponsorship of 
the program, and has continued to conduct additional trainings after the conclusion of funding from 
Merck. Professor Liechty explained the importance of this relationship: 
The most critical success factor for the program was that it was completely intertwined 
with KEPI. If we had developed an independent training program, I don’t think it would 
have been as effective or had any chance of being sustained. But since the government 
had contributed substantial resources, they felt ownership and wanted to see it carried 
on. 
Embedding training curriculum into existing medical and nursing schools can also improve the 
sustainability of program impact. For instance, although not initially a focus of MVN-A, the Zambia 
program identified a critical need for pre-service training on vaccine delivery for nurses. As Dr. Paul 
Seddon, Co-Director of MVN-Z, describes: 
One of the lessons we learned early on was that updating the training modules wasn’t 
enough; it was a matter of health care workers not being adequately prepared by their 
undergraduate education. We needed to go back and strengthen pre-service training. 
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Prior to conducting the training, MVN-Z completed a comprehensive needs assessment to adapt existing 
curriculum for the nursing audience. The first training, in 2011, was attended by nineteen nursing tutors 
and clinical instructors from sixteen different nursing schools, who proceeded to train other nursing tutors 
at their respective schools. Professor Mary Shilalukey Ngoma, Co-Director of the program, describes the 
impact: “When the nursing tutors were trained, we immediately saw the value of peer support. The nurses 
very naturally, spontaneously, and extensively trained others, and the hands-on instruction was hugely 
effective.” Building upon this initial success, MVN-Z plans to train individuals at the country’s remaining 
twenty-three nursing schools in 2012. 
5. Use Locally-Adapted Curricula and Teaching Techniques 
All four MVN-A programs grounded 
their trainings in context-appropriate 
and locally adapted curricula. The 
existing standard at the outset of the 
program was the EPI Mid-Level 
Manager course, which was originally 
developed by WHO in 1991 and later 
adapted by the WHO Regional Office 
in Africa. Although built on rigorous 
and credible content, the materials 
were comprised of 24 dense modules, 
making them difficult for immunization 
managers to digest, and required far 
more instruction time than was 
feasible for busy health care workers 
to spend away from the hospital or 
clinic.52  
Recognizing these limitations, the Kenya program used its pool of trainer-of-trainers (TOTs) to condense 
the WHO modules and adapt them to the Kenyan context, focusing on priorities identified by the needs 
assessment. The group of TOTs selected 13 of the WHO modules for inclusion and condensed them into 
shorter presentations. They also developed new materials on specific local needs not addressed by the 
WHO curriculum, such as disease surveillance and cold chain maintenance (see section “Conduct a 
Rigorous Needs Assessment and Ongoing M&E,” above, for additional detail). The programs in Uganda 
and Zambia undertook a similar process of condensing and adapting the modules, incorporating 
consultation with a range of stakeholders, including local ministries of health, WHO, and UNICEF.  
                                                       
52 Although WHO updated the course in 2008, and also condensed it into eight modules, this was too late for the programs 
to use these materials at the start of their trainings.  
 
Group discussions during a 2009 MVN-Z training 
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In order to improve learning and knowledge retention, several programs utilized adult learning techniques, 
including active participation, group discussions, role playing, and hands-on practice. In partnership with 
The University of Zambia School of Education, MVN-Z incorporated learning techniques such as 
brainstorming, role-playing exercises, and cooperative problem solving. The trainers worked to refine 
these facilitation methods over time by engaging an outside consultant to assess strengths, weaknesses, 
and areas of improvement. An evaluation of the program demonstrated that the trainings were successful 
in increasing the knowledge and skills of the participants in multiple key areas, including ability to apply 
problem solving approaches, plan immunization services, and monitor immunization activities.53 Similarly, 
the MVN-K program used a range of adult learning techniques in its courses, and even created a new 
module on the pedagogical concepts in EPI training to educate participants on how they might apply the 
same techniques while supervising others. 
6. Incorporate Supportive Supervision 
Continuous supportive supervision following initial training is part of a comprehensive long-term capacity 
building process.54 Supportive supervision is on-site training that utilizes a series of short, objective 
checklists to structure targeted sessions of observation and feedback. The on-site nature of the training 
both serves as a regular touch point to identify structural issues early and allows staff to remain at their 
posts and attend to the management of their local immunization centers. Ideally, the process also should 
include management training on strategic planning and effective monitoring of progress against goals at 
the local level. 
MVN-Mali piloted a supportive supervision program after an interim evaluation revealed deficiencies in 
information transfer from those trained at the district level to the health center-level workers.55,56 The aim 
was to ensure that knowledge and practice were actually improving at all levels. Dr. Fanta Niare 
Dembele, Program Coordinator, explained the rationale behind this approach: 
There can be a big gap between what you learn during training and the implementation of 
that learning in reality. It is impossible to gauge from a distance if the training is having an 
effect; you need to be there with the health workers when they administer vaccines and 
correct them if it is not done correctly. 
MVN-Mali’s supportive supervision program was launched in 2008 and carried out in eight community 
health centers every three months. The program design favored a focused and participatory approach 
and covered four supervisory tools, including injection safety, techniques and communications for 
immunization, program management, and surveillance. Final coverage surveys indicated that supportive 
                                                       
53 Anitha Menon, “Overall Effectiveness of the Mid-Level Management Course for EPI Managers,” Unpublished MVN-A 
Document.  
54 Children's Vaccine Program at PATH, “Guidelines for Implementing Supportive Supervision: A step-by-step guide with 
tools to support immunization,” (Seattle: PATH, 2003). 
55 Interim assessment revealed higher performance at the regional and district levels and insufficient knowledge among 
those conducting supervisory training.  
56 Milstien, “Strengthening Immunization in a West African Country: Mali.” 
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supervision was effective after just one year of implementation. Immunization coverage rates increased 
by almost 14 percentage points, resulting in an overall coverage rate of 90 percent.57,58 There were also 
large decreases in drop-out rates – which declined to 5% or less at all centers – as well as reductions in 
stock-outs and the percentage of children vaccinated outside of scheduled intervals.59 
Both MVN-Mali and UITP in Uganda have recommended that supportive supervision be adopted by 
national EPI programs in the future. The Mali program’s directors and TAG agreed that “supportive 
supervision has the potential to greatly improve immunization training activities through a simple and 
inexpensive approach.”60 Similarly, the UITP final evaluation highlighted that supportive supervision was a 
powerful tool to ensure that knowledge acquired in the trainings was being successfully translated into 
practice and retained over time. 
7. Facilitate and Support Regular Convening and Communication 
When administering a multi-country immunization program, the facilitation of regular learning and 
communication between sites can be a powerful tool for improving program effectiveness. This orientation 
toward learning for improvement was reflected in MVN-A, as program leadership universally agreed that 
one of the most valuable components of the program was convening to share learning and experiences 
across countries. The Merck Company Foundation supported three such meetings over the life of MVN-A, 
bringing together key program leadership in Paris, France, in 2005; Haarlem, Netherlands, in 2008; and 
Washington, D.C., in 2011. 
The value of these peer learning meetings was undisputed, providing program leadership the opportunity 
to share different approaches to the work and collaborate on potential solutions to common challenges. In 
fact, program leaders across Africa, the U.S., and the EU all expressed a strong desire for more regular, 
real-time opportunities for cross-country communication. Dr. Fred Wabwire-Mangen, Co-Director of the 
Uganda program, explains: 
We really would have benefited from more collaboration between the partner countries. It 
would have been particularly helpful to learn from the experiences of Kenya and Mali, 
who had been operating longer than we had. More country visits, network meetings, and 
conference calls would have helped quite a bit, as I’m sure the different country programs 
were experiencing similar challenges. 
Reflecting upon this desire for additional facilitation of cross-program communication, leaders from Merck 
learned a valuable lesson about the importance of consistently enabling meaningful sharing of 
experiences. Brenda D. Colatrella, Executive Director of Merck’s Office of Corporate Responsibility, 
points out that it is essential to plan and earmark funds for these valuable activities:  
                                                       
57 MVN-Mali data were analyzed for coverage of DTP1, DTP3, yellow fever, and measles vaccines by 12 months of age. 
Coverage increased nationwide due to several initiatives, but not to the same degree as in the test centers. Controls centers 
experienced an increase of coverage of 4.5 percentage points, resulting in coverage of 78.5%.  
58 Milstien, “Supportive Supervision Activities in Mali Improve the Quality of Immunization Services.” 
59 Ibid. 
60 Ibid. 
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While there was sufficient funding for the program, there was less funding available for 
operational support. We fell short in terms of projecting needs of the operational budget 
to facilitate activities such as summits and convenings of the program partners. We 
learned that, going forward, it’s important to make those commitments explicit and plan 
for them accordingly.  
Conclusion 
Over the past ten years, the MVN-A program trained more than 1,600 immunization managers, 
significantly building the capacity of vaccine delivery systems in Kenya, Mali, Uganda, and Zambia. As 
The Merck Company Foundation concludes its decade-long support of MVN-A, it hopes that this 
experience provides lessons that may be helpful to other funders, governments, and NGOs designing or 
implementing vaccine delivery training programs around the world. In particular, the MVN-A experience 
surfaced seven key lessons that, when applied together, can increase both program effectiveness and 
sustainability.  
Comprehensive immunization manager training programs can powerfully improve the skills and 
confidence of the health care workers responsible for day-to-day administration of vaccines. Going 
forward, it is critical that immunization training be elevated as a priority on the global health agenda, 
ensuring that adequate funding and attention are committed to this important global health intervention. 
Immunization delivery training, especially when combined with other essential capacity building efforts, 
has the potential to save the lives of millions of children each year. 
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Appendix: Stakeholders Interviewed 
Pamela Achieng 
Trainer, MVN-K 
Training Manager, Kenya Expanded Program on Immunization 
 
Nicholas Ayebazibwe 
Project Officer, UITP 
Professor, Makerere University Institute of Public Health, Uganda 
 
Jhilmil Bahl 
Capacity Building Specialist, World Health Organization Regional Office for Africa 
 
Alain Barry 
Manager for Mali and other West African countries, Institutional Business Africa, Merck & Company 
 
David Chemirmir 
Country Sales Manager, Kenya, Merck & Company 
 
Michael Chimbipa 
Facilitator, MVN-Z 
Provincial Expanded Program on Immunization Officer, Solwezi, Zambia 
 
Brenda D. Colatrella 
Executive Director, Office of Corporate Responsibility, Merck & Company 
 
James Conway 
Co-Director, MVN-K 
Associate Professor of Pediatrics, University of Wisconsin School of Medicine 
 
Fanta Niare Dembele 
Program Coordinator, MVN-Mali 
District Manager, Expanded Program on Immunization, Mali 
 
Bany Diaby 
Facilitator, MVN-Mali 
Supervisor, Expanded Program on Immunization, Mali 
 
Niraj Doshi 
Manager, HIV Access Program, East & Southern Africa, Merck and Company 
 
Laura Efros 
Senior Director, Vaccine Public Policy, Merck & Company 
 
Fabian Esamai 
Co-Director, MVN-K 
Professor of Child Health and Pediatrics, Moi University School of Medicine 
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Mark Feinberg 
Vice President, Medical Affairs and Policy, Merck & Company 
 
Alan Hinman 
Co-Director, UITP 
Director for Programs, Center for Vaccine Equity, Task Force for Global Health 
 
Annet Kisakye 
EPI Team Leader, WHO Country Office Uganda 
Surveillance Officer, World Health Organization 
 
Nouhoum Kone 
Technical Advisory Committee Member, MVN-Mali 
Assistant Director of Health, Ministry of Health, Mali 
 
Karen Kotloff 
Co-Director, MVN-Mali 
Professor of Pediatrics, University of Maryland Medical Center 
 
Edward A. Liechty 
Co-Director, MVN-K 
Professor of Pediatrics, Indiana University School of Medicine 
 
Adel A. F. Mahmoud 
Former President, Merck Vaccines, Merck & Company 
Lecturer with the rank of Professor in Molecular Biology and Public Policy, Woodrow Wilson School 
 
Julie Milstien 
Program Staff, MVN-Mali 
Adjunct Associate Professor of Medicine, University of Maryland School of Medicine 
 
Evans Mpabalwani 
Course Director, MVN-Z 
Pediatrician and Virologist, Department of Pediatrics and Child Health, University Teaching 
Hospital, Lusaka, Zambia 
 
David Mukanga 
Executive Director, African Field Epidemiology Network 
 
Kris Natarajan 
Former Director, Global Health Partnerships and Global Vaccine Initiatives, Merck & Company 
Senior Technical Advisor to the CEO, Center for Health Sciences Training, Research and Development 
 
Mary Shilalukey Ngoma 
Co-Director, MVN-Z 
Associate Professor of Pediatrics and Child Health, University Teaching Hospital, Lusaka, Zambia 
 
Godfrey Phiri 
Director of Organization, MVN-Z 
Postgraduate Student in Orthopedic Surgery, University Teaching Hospital, Lusaka, Zambia 
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Melanie Ribeiro 
Vaccine Manager, Kenya, Merck & Company 
 
Victor Sakala 
HIV/AIDS Specialist, Zambia, Merck & Company 
 
Paul Seddon 
Co-Director, MVN-Z 
Professor of Pediatrics, Brighton Sussex Hospital 
 
Josephine Simwinga 
Chief EPI Officer, Ministry of Community Development and Social Services 
 
Samba O. Sow 
Program Principal Investigator, MVN-Mali 
Coordinator, Center for Vaccine Development-Mali and Associate Professor of Medicine, University of 
Maryland School of Medicine 
 
Steve Stewart 
Health Educator, Global Immunization Division, Center for Disease Control 
 
Walter Straus 
Global Director for Scientific Affairs – Vaccines, Merck & Company 
 
Winifred Tabaaro 
Trainer, UITP 
Training Officer, Ugandan National Expanded Program on Immunization, Ministry of Health, Uganda 
 
Fred Wabwire-Mangen 
Co-Director, UITP 
Associate Professor of Epidemiology, Makerere University Institute of Public Health, Uganda 
 
Collin West 
Facilitator, MVN-Z 
Medical Officer, Ministry of Health, Zambia 
 
Karen A. Wilkins 
Former MVN-A Advisory Board Member 
Deputy Branch Chief, Strengthening Immunization Systems, Center for Disease Control
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